NASDAQ:BRNS Barinthus Biotherapeutics Q3 2026 Earnings Date & Estimates $0.74 0.00 (0.00%) As of 10/8/2026 Barinthus Biotherapeutics is scheduled to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. The conference call is scheduled for 12:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 6, 2026TimeBefore Market OpensConference Call12:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Barinthus Biotherapeutics in Q3 2026Barinthus Biotherapeutics is expected to post earnings of -$0.27 per share on revenue of $0.22 million. In the same quarter a year earlier Barinthus Biotherapeutics reported -$0.36 per share. Barinthus Biotherapeutics last reported on August 7, 2026, posting -$0.26 per share and beating the -$0.28 consensus estimate. Barinthus Biotherapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.27Expected Revenue$0.22 millionPrior-Year EPS-$0.36Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.26 (Beat by +$0.02)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Barinthus Biotherapeutics Q3 2026 Earnings FAQ When does Barinthus Biotherapeutics report Q3 2026 earnings? Barinthus Biotherapeutics (NASDAQ:BRNS) is scheduled to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. What time is Barinthus Biotherapeutics' Q3 2026 earnings call? Barinthus Biotherapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Barinthus Biotherapeutics? Analysts expect Barinthus Biotherapeutics to post earnings of -$0.27 per share for Q3 2026. How much revenue is Barinthus Biotherapeutics expected to report? The consensus revenue estimate for Barinthus Biotherapeutics is $0.22 million for Q3 2026. Barinthus Biotherapeutics Earnings HeadlinesBarinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsAugust 24, 2026 | globenewswire.comBarinthus Biotherapeutics PLC ADR BRNSJuly 3, 2026 | morningstar.comMIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 9 at 1:00 AM | Banyan Hill Publishing (Ad)Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNSMay 11, 2026 | businesswire.comBarinthus Biotherapeutics: Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate DevelopmentsApril 30, 2026 | finanznachrichten.deBarinthus in Green on Bringing Out Quarterly NumbersApril 30, 2026 | baystreet.caSee More Barinthus Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Barinthus Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Barinthus Biotherapeutics and other key companies, straight to your email. Email Address About Barinthus BiotherapeuticsBarinthus Biotherapeutics (NASDAQ:BRNS) plc (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company developing T-cell immunotherapies designed to treat autoimmune diseases. Its approach is intended to selectively modulate disease-causing immune responses while preserving broader immune-system function. The company’s pipeline includes VTP-1000, an investigational therapy being developed for celiac disease. Barinthus is also advancing additional preclinical and clinical programs that use its proprietary immune-modulation technologies to target other autoimmune conditions. The company’s development strategy focuses on antigen-specific tolerance, which aims to reduce harmful immune reactions against particular tissues or proteins. Barinthus Biotherapeutics was formerly known as Vaccitech plc and adopted its current name in 2024 as it sharpened its focus on autoimmune disease. The company is headquartered in the United Kingdom and operates as an international biotechnology business serving global healthcare and pharmaceutical markets. William Enright serves as chief executive officer.View Barinthus Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
